tiprankstipranks
Trending News
More News >
Ramsay Generale de Sante (FR:GDS)
:GDS
Advertisement

Ramsay Generale de Sante (GDS) AI Stock Analysis

Compare
1 Followers

Top Page

FR:GDS

Ramsay Generale de Sante

(LSE:GDS)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
€10.00
▲(1.63% Upside)
The overall stock score is primarily influenced by financial performance, which shows stable revenue growth and strong cash flow but is hindered by profitability challenges and high leverage. Technical analysis indicates a bearish trend, and valuation metrics highlight financial losses and lack of dividends.

Ramsay Generale de Sante (GDS) vs. iShares MSCI France ETF (EWQ)

Ramsay Generale de Sante Business Overview & Revenue Model

Company DescriptionRamsay Generale de Sante (GDS) is a leading private healthcare provider in France, operating a comprehensive network of hospitals and clinics. The company offers a wide range of medical services including surgery, oncology, obstetrics, rehabilitation, and mental health care. GDS is part of the Ramsay Health Care Group, a global healthcare organization, and is renowned for its commitment to quality care and patient safety.
How the Company Makes MoneyRamsay Generale de Sante generates revenue primarily through the provision of medical and healthcare services across its network of hospitals and clinics. The company charges patients or their insurance providers for treatments, procedures, and consultations. Additionally, GDS benefits from partnerships with public health agencies and contracts with private health insurers, ensuring a steady stream of income. Ancillary services such as diagnostics, laboratory tests, and pharmacy sales also contribute to the company's revenue. GDS's focus on efficiency and high-quality service delivery helps maintain its profitability in the competitive healthcare sector.

Ramsay Generale de Sante Financial Statement Overview

Summary
Ramsay Generale de Sante shows stable revenue growth and strong cash flow generation, which are positive indicators. However, challenges with profitability and high leverage could impact financial stability.
Income Statement
55
Neutral
Ramsay Generale de Sante shows a modest revenue growth rate of 1.91% in the most recent year, indicating stability in revenue generation. However, the company faces challenges with profitability, as evidenced by a negative net profit margin. The gross profit margin remains strong, suggesting efficient cost management, but the negative net income highlights issues in controlling other expenses or financial costs.
Balance Sheet
50
Neutral
The company's balance sheet reflects a high debt-to-equity ratio, indicating significant leverage which could pose financial risks. The return on equity is negative, driven by the net losses, which is a concern for investors. However, the equity ratio is reasonable, suggesting a balanced asset structure.
Cash Flow
65
Positive
Ramsay Generale de Sante demonstrates strong cash flow management with a significant free cash flow growth rate of 25.21%. The operating cash flow to net income ratio is robust, indicating effective cash generation relative to accounting profits. However, the free cash flow to net income ratio suggests that cash flow is not fully translating into profitability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.24B5.24B5.01B4.70B4.30B4.02B
Gross Profit1.21B4.08B3.94B3.72B3.41B3.20B
EBITDA474.20M599.70M591.30M656.30M691.00M604.00M
Net Income-54.10M-54.10M-53.90M49.40M118.40M65.00M
Balance Sheet
Total Assets6.84B6.84B6.90B6.96B6.79B6.68B
Cash, Cash Equivalents and Short-Term Investments384.00M384.00M381.30M362.90M143.50M620.00M
Total Debt4.08B4.08B4.06B4.15B3.97B3.85B
Total Liabilities5.66B5.66B5.67B5.68B5.55B5.58B
Stockholders Equity1.15B1.15B1.19B1.25B1.21B1.07B
Cash Flow
Free Cash Flow498.30M550.90M418.30M426.70M68.90M475.90M
Operating Cash Flow641.10M693.70M586.80M598.90M262.50M652.30M
Investing Cash Flow-179.30M-138.40M-180.50M-175.40M-471.10M-181.40M
Financing Cash Flow-589.85M-550.20M-401.50M-197.10M-264.20M-390.60M

Ramsay Generale de Sante Technical Analysis

Technical Analysis Sentiment
Negative
Last Price9.84
Price Trends
50DMA
10.24
Negative
100DMA
10.39
Negative
200DMA
10.56
Negative
Market Momentum
MACD
-0.09
Negative
RSI
36.11
Neutral
STOCH
8.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GDS, the sentiment is Negative. The current price of 9.84 is below the 20-day moving average (MA) of 9.96, below the 50-day MA of 10.24, and below the 200-day MA of 10.56, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 36.11 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:GDS.

Ramsay Generale de Sante Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
939.00M15.7510.19%1.12%-0.95%27.67%
70
Outperform
301.14M13.556.95%4.50%9.58%-6.69%
63
Neutral
2.60B19.7413.93%0.47%6.97%-5.59%
58
Neutral
1.50B-32.36-1.49%1.98%85.87%
48
Neutral
€1.09B-4.36%4.70%-0.33%
40
Neutral
1.91B-4.44-23.89%8.43%-102.06%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:GDS
Ramsay Generale de Sante
9.88
-4.62
-31.86%
GB:0OPS
Clariane
4.19
2.39
132.78%
GB:0OR2
LNA Sante SA
28.80
6.08
26.76%
GB:0NEX
Orpea SA
11.83
4.54
62.28%
GB:0O1O
VETOQUINOL
79.70
-5.18
-6.10%
GB:0NM7
Virbac SA
310.75
-82.97
-21.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 03, 2025